AbbVie: Unique Mix Of Growth And Value

RI Research1.57K FollowersFollow5ShareSavePlay(10min)Comment(1)SummaryAbbVie earns a Strong Buy rating, driven by exceptional execution post-Humira patent cliff and robust 2025 share price outperformance.Skyrizi and Rinvoq are rapidly replacing Humira, delivering 47% and 35% YoY growth in Q3 2025, with patent protection into the 2030s.ABBV's business mix is diversified, with immunology and neuroscience segments together driving double-digit revenue growth and supporting strong EPS prospects.Despite a robust rally, ABBV remains attractively valued with a compressing forward P/E, a 3.1% dividend yield, and prudent capital allocation.hapabapa/iStock Editorial via Getty Images I continue exploring potential new opportunities in the Healthcare (XLV) sector, especially across pharmaceutical giants as they were underperforming notably during the AI frenzy. While exploring potential opportunities I was a little bit surprised there wasThis article was written byRI Research1.57K FollowersFollowWith a decade at a Big 4 audit firm specializing in the banking, mining, and energy sectors, I bring a strong foundation in finance and strategy. Currently, I serve as the Head of Finance for a leading owner and operator of retail real estate, where I oversee complex financial operations and strategy. I’ve been an active investor in the U.S. stock market for 13 years, starting with my very first paycheck. Over time, my portfolio has evolved to reflect a balanced approach, with a growing focus on value stocks while maintaining solid exposure to growth opportunities. My investment philosophy is rooted in thorough research and a long-term perspective, which has helped me navigate various market cycles successfully. I aim to bring value to Seeking Alpha by uncovering promising under-the-radar stocks that may not yet be on the broader market’s radar. My background in auditing and finance, combined with years of hands-on investing experience, allows me to provide unique insights and actionable ideas for fellow investors.Analyst’s Disclosure:I/we have a beneficial long position in the shares of ABBV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.Recommended For You